IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been assigned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $256.80.

A number of analysts recently commented on the stock. SVB Leerink initiated coverage on shares of IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Barclays lifted their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Robert W. Baird lifted their target price on shares of IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Finally, BTIG Research initiated coverage on shares of IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price for the company.

IQVIA Stock Down 2.8 %

IQV stock opened at $234.08 on Friday. The company has a market cap of $42.49 billion, a P/E ratio of 32.11, a P/E/G ratio of 2.31 and a beta of 1.50. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73. The company’s 50-day moving average price is $245.35 and its 200 day moving average price is $222.77. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.54 earnings per share. On average, research analysts expect that IQVIA will post 10.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,285 shares of company stock valued at $10,331,003. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC grew its stake in IQVIA by 2.9% during the third quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after buying an additional 80,189 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock valued at $532,070,000 after purchasing an additional 93,194 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of IQVIA by 3.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after purchasing an additional 77,422 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after purchasing an additional 1,597,003 shares during the period. Finally, Capital Research Global Investors boosted its stake in shares of IQVIA by 42.2% in the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after purchasing an additional 592,372 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.